Bone density in chronic schizophrenia with long-term antipsychotic treatment: preliminary study
- PMID: 21253412
- PMCID: PMC3022315
- DOI: 10.4306/pi.2010.7.4.278
Bone density in chronic schizophrenia with long-term antipsychotic treatment: preliminary study
Abstract
Objective: Decreased bone mineral density has been found in the chronic schizophrenic patients who have been given a long-term administration of antipsychotics. Hyperprolactinemia from the antipsychotics and the negative symptom of schizophrenia were considered as the causes for this finding. In this study, the effect of hyperprolactinemia and the negative symptom of schizophrenia on bone mineral density was investigated on male schizophrenic patients.
Methods: The cross-sectional study was carried out with the subjects of 45 male schizophrenic patients who have undertaken the monotherapy with risperidone, olanzapine and clozapine for at least one year. The demographic factors, clinical symtoms, bone mineral density and hematological test were examined for all the subjects.
Results: No significant relationship was found between hyperprolactinemia and the decreased bone mineral density in the subjects. The negative schizophrenia symptom of the subjects showed a significant effect on the decreased bone mineral density.
Conclusion: The decreased bone mineral density finding in the male schizophrenic patients may be caused by the negative schizophrenia symptom rather than the hyperprolactinemia due to the antipsychotics. Additional studies are further required regarding other factors that may affect the decreased bone mineral density such as activity, calcium intake and exposure to sunlight.
Keywords: Antipsychotics; Bone density; Hyperprolactinemia; Negative symptoms; Schizophrenia.
Similar articles
-
[Decrease in mineral bone density in schizophrenic patients treated with 2nd generation antipsychotics].Psychiatr Pol. 2005 Nov-Dec;39(6):1173-84. Psychiatr Pol. 2005. PMID: 16526183 Polish.
-
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].Encephale. 2005 Mar-Apr;31(2):235-46. doi: 10.1016/s0013-7006(05)82390-5. Encephale. 2005. PMID: 15959450 Review. French.
-
The Effects of Prolactin-Raising and Prolactin-Sparing Antipsychotics on Prolactin Levels and Bone Mineral Density in Schizophrenic Patients.Noro Psikiyatr Ars. 2014 Sep;51(3):205-210. doi: 10.4274/npa.y6628. Epub 2014 Sep 1. Noro Psikiyatr Ars. 2014. PMID: 28360627 Free PMC article.
-
Bone loss associated with hyperprolactinemia in patients with schizophrenia.Clin Schizophr Relat Psychoses. 2013 Oct;7(3):115-23. doi: 10.3371/CSRP.KISE.020113. Clin Schizophr Relat Psychoses. 2013. PMID: 23395836 Clinical Trial.
-
Sleep disturbances in patients with schizophrenia : impact and effect of antipsychotics.CNS Drugs. 2008;22(11):939-62. doi: 10.2165/00023210-200822110-00004. CNS Drugs. 2008. PMID: 18840034 Review.
Cited by
-
Effects of Antipsychotics on Bone Mineral Density in Patients with Schizophrenia: Gender Differences.Clin Psychopharmacol Neurosci. 2016 Aug 31;14(3):238-49. doi: 10.9758/cpn.2016.14.3.238. Clin Psychopharmacol Neurosci. 2016. PMID: 27489377 Free PMC article. Review.
-
Does clozapine really affect bone mineral density? An experimental study.J Orthop Surg Res. 2021 Sep 15;16(1):558. doi: 10.1186/s13018-021-02695-w. J Orthop Surg Res. 2021. PMID: 34526046 Free PMC article.
-
Bone Mineral Density as a Marker of Cumulative Estrogen Exposure in Psychotic Disorder: A 3 Year Follow-Up Study.PLoS One. 2015 Aug 26;10(8):e0136320. doi: 10.1371/journal.pone.0136320. eCollection 2015. PLoS One. 2015. PMID: 26309037 Free PMC article.
-
Atypical antipsychotic drugs inhibit trabecular bone accrual in C57BL/6J mice.Int J Body Compos Res. 2013 Jan 28;11(1):21-24. Int J Body Compos Res. 2013. PMID: 24839401 Free PMC article.
-
A trans-ethnic two-stage polygenetic scoring analysis detects genetic correlation between osteoporosis and schizophrenia.Clin Transl Med. 2020 Feb 27;9(1):21. doi: 10.1186/s40169-020-00272-y. Clin Transl Med. 2020. PMID: 32107650 Free PMC article.
References
-
- Christiansen C. Skeletal osteoporosis. J Bone Miner Res. 1993;8(Suppl 2):S475–S480. - PubMed
-
- Wark JD. Osteoporotic fractures : background and prevention strategies. Maturitas. 1996;23:193–207. - PubMed
-
- Slemenda C. Prevention of hip fractures: risk factor modification. Am J Med. 1997;103:65S–71S. discussion 71S-73S. - PubMed
-
- Ebeling PR. Osteoporosis in men. New insights into aetiology, pathogenesis, prevention and management. Drugs Aging. 1998;13:421–434. - PubMed
-
- Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997;7:407–413. - PubMed
LinkOut - more resources
Full Text Sources